JCOM Paid Subscribers LOG IN user name: password:   Forgot password?		J Clin Outcomes Manage  2000 Jul;7(7):23-26 Use of RSV-IGIV: one hospital's experience Lee KR, Teter BW, Margolis KA, DeVincenzo JP, Barrett FF Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) is approved for prevention of RSV disease in children younger than 24 months with bronchopulmonary dysplasia or premature birth. The authors report on compliance and other outcomes in patients receiving this drug during 2 RSV seasons. Original research Search the Turner White index to find abstracts of articles published in JCOM.
New issues are posted one month following publication of the printed journal. View past issue archives:    2011    2010    2009    2008    2007    2006    2005    2004    2003     2002     2001     2000     1999 Hospital Physician     JCOM     Seminars in Medical Practice Hospital Physician Board Review Manuals About TWC    Subscribe    Contact TWC    Home    Search   Site Map Copyright © 2013, Turner White Communications Updated 7/14/09 • nvf